GlobeNewswire Inc | Nov 11, 2021 07:00AM EST

November 11, 2021

DURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Chimerix(NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced upcoming data presentations at theSociety for Neuro-Oncology (SNO) Annual Meeting 2021, which will be held in Boston, MA from November 19-21, 2021.

Details for the late-breaking plenary oral presentation are as follows:

Title:Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patientsAbstract Number:LTBK-05Date and Time:November 20, 2021from9:37 a.m. 9:50 a.m. ETPresenter: Isabel Arrillaga-Romany, M.D., Ph. D., Massachusetts General Hospital

Details for additional oral and poster presentations are as follows:

Title:Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomasAbstract Number:CTNI-27Date and Time:November 19, 2021from7:30 p.m. - 9:30 p.m. ETPresenter:Yazmin Odia, M.D., M.S., FAAN, Miami Cancer Institute

Title:Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients Abstract Number:CTNI-36Date and Time:November 19, 2021from7:30 p.m. - 9:30 p.m. ETPresenter:Sharon L. Gardner, M.D., New York University School of Medicine

Title:Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose has a strong antiproliferative effect on medulloblastoma cells Abstract Number:EXTH-68Date and Time:November 19, 2021from7:30 p.m. - 9:30 p.m. ETPresenter:Georg Karpel-Massler, M.D., Ph.D., Ulm University

Title:Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in GlioblastomaAbstract Number:TAMI-17Date and Time:November 19, 2021from7:30 p.m. - 9:30 p.m. ETPresenter:Trang T. Nguyen, Ph.D., Columbia University

Title:Harnessing Cellular Stress for Immune Targeting of DIPGsAbstract Number:EXTH-30Date and Time:November 19, 2021from7:30 p.m. - 9:30 p.m. ETPresenter:Donghang Cheng, Ph.D., University of Texas MD Anderson Cancer Center

Title:Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201Abstract Number:BIOM-28Date and Time:November 21, 2021from11:35 a.m. 11:45 a.m. ETPresenter:Evan Cantor, M.D., J.D., Washington University at St. Louis

AboutChimerix

Chimerix is a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M mutant glioma. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:

Investor Relations:Michelle LaSpaluto919-972-7115ir@chimerix.com

Will OConnorStern Investor Relations212-362-1200will@sternir.com